Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results

Cancer statistics, 2024

Rebecca L. Siegel, Angela N. Giaquinto, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2024 · 9K citations · Full text

Medicine, Oncology, Cancer Control +16

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh et al. · The Lancet · 2017 · 2.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Enli Liu, David Marín, Pinaki P. Banerjee et al. · New England Journal of Medicine · 2020 · 2.1K citations · Full text

Life Sciences, Immunology, Oncology +17

Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 2006 to 2016: A systematic analysis for the Global Burden of Disease study.

Christina Fitzmaurice · Journal of Clinical Oncology · 2018 · 1.7K citations · Full text

Medicine, Health Policy, Oncology +17

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Frederick L. Locke, David B. Miklos, Caron A. Jacobson et al. · New England Journal of Medicine · 2021 · 1.5K citations · Full text

Medicine, Hematology, Oncology +8